A sub-study in 37 patients in the pivotal trial CLEOPATRA, showed no evidence of drug-drug interaction between Perjeta and Herceptin and between Perjeta and docetaxel. In addition no clinical relevant pharmacokinetic interaction of co- administered docetaxel or Herceptin on Perjeta was evident, based on the population pharmacokinetics analysis. This lack of drug-drug interaction was confirmed by pharmacokinetic data from the NEOSPHERE and APHINITY studies.
Five studies have evaluated the effects of Perjeta on the pharmacokinetics of co- administered cytotoxic agents, docetaxel, paclitaxel, gemcitabine, capecitabine, carboplatin and erlotinib. There was no evidence of any pharmacokinetics interaction between Perjeta and any of these agents. The pharmacokinetics of Perjeta in these studies were comparable to those observed in single-agent studies.